An activating point mutation in FGFR3C746C > G, encoding the FGFR3 S249C oncoprotein, accounts for 48–71% of all FGFR3 mutations in non‐invasive urothelial cell carcinoma 14, 15. This evidence concerns the gene FGFR3 and transitional cell carcinoma.